OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting Strategic Progress
Dear OneMedNet Shareholders, Partners, and Family,
Following a year of significant progress, OneMedNet is navigating 2025 with strong momentum, making substantial strides in expanding our market presence, enhancing our Real-World Data platform, and developing an AI driven tool set to anonymize and De-identify data across multiple industries. My leadership team and I feel it is important that you know our key achievements, including onboarding five major data marketplaces, surpassing 121 million clinical exams in our network, and charting the path forward as we capitalize on the growing demand for de-identified data starting with regulatory-grade RWD.
We are excited about OneMedNet's scalable, tech-enabled model that positions us for sustained growth and long-term value creation.
2024 Highlights
AI-Powered Platform: Our federated iRWD™ platform leverages cost-effective AI tools to search, de-identify, and curate precise datasets at scale. These tools serve healthcare as well as industries like finance, telecom, and retail through advanced anonymization technology.
Expanded Market Reach: We are now partnered with five leading data marketplaces—Amazon Data Exchange (AWS), Protege AI, Bayer Data Marketplace, Datavant, and HealthVerity. These platforms collectively span multiple segments of the healthcare data ecosystem, including real-world evidence, clinical trial optimization, payer-provider data exchange, and AI model training. From AWS's enterprise-scale infrastructure to Datavant and HealthVerity's leadership in de-identified health data, and Protege AI's focus on model-ready datasets, they form a powerful network supporting innovation across life sciences, pharma, and digital health.
Network Growth: Our partnerships with over 1,400 hospital and healthcare provider sites have grown our medical imaging-rich RWD repository to over 121 million clinical exams, expanding organically by ~5% annually through daily patient care activities.
Amplified Brand Presence: Increased participation in industry trade shows and targeted campaigns has strengthened stakeholder engagement, with imaging's role in longitudinal patient records resonating as a key differentiator. This momentum generated over 130 qualified leads—a threefold increase from previous years—demonstrating rising market interest. The growing demand for these services is further evidenced by many customers consistently returning to OneMedNet first for their data needs, driven by their positive experiences with our platform, quality data and services.
Diverse Customer Base: Our healthcare regulatory-grade datasets are licensed by leading life sciences organizations for clinical trials, regulatory submissions, and AI model development, reflecting strong market validation.
Regulatory Compliance: Our datasets meet stringent FDA and international standards, enabling real-world evidence (RWE) for submissions, post-market surveillance, and research.
AI Innovation: We provide foundational data to train and validate AI models in medical imaging and diagnostics, accelerating advancements in precision medicine.
What Sets Us Apart
OneMedNet does not just collect raw data. We deliver:
AI-assisted de-identification and anonymization, applicable across industries like healthcare, finance, telecom, and retail.
OneMedNet delivers premium, purpose-built RWD, not raw data.
Curated, regulatory-grade datasets
Longitudinal tracking across multiple care events.
Imaging-centric iRWD™, enhanced by custom cohort matching and AI-powered refinement.
High customer satisfaction, driving repeat orders from leading life sciences organizations.
The Opportunity Ahead
The need for RWD has never been greater. The traditional model of running lengthy, expensive clinical trials is being disrupted. Regulators like the FDA and European Medicines Agency (EMA) are increasingly encouraging the use of RWE as part of the approval process.
According to McKinsey generative AI and RWD could unlock $60 billion to $110 billion in annual value across the pharmaceutical and medical-device sectors. Recent industry analysis projects healthcare data growth at a 36% CAGR through 2030, far outpacing other sectors. OneMedNet is uniquely positioned to capture this multi-billion-dollar opportunity, leveraging our scalable platform, extensive network, and AI-driven capabilities.
Subscription-Based pricing model
We have added a subscription-based Data License Agreement (DLA) structure to drive Annual Recurring Revenue (ARR). Our platform now supports near real-time data updates, allowing access to curated, regulatory-grade datasets through flexible, recurring licenses. This enhances scalability, strengthens network effects, and aligns with long-term demand for high-quality RWD. Our partner hospitals and clinics share the revenue, incentivizing network expansion and data depth.
Looking Forward
Our three pillars—Platform, Partners, and People—anchor our strategy. Our proven AI de-identification and anonymization across industries, iRWD™ platform, growing network of provider sites, and experienced leadership team, with expertise in AI, cloud solutions, healthcare, regulatory compliance, and M&A, are aligned for execution. We are intensifying investor outreach and communication to highlight our progress and vision.
To our shareholders: Thank you for your support. While stock price fluctuations may not reflect our full potential, we are building enduring value through data, scalability, and relevance to the future of healthcare and beyond.
Sincerely,
Aaron Green
President and CEO
OneMedNet Corporation
Investor Relations - https://www.onemednet.com/investor-relations/
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD™ platform. This isn't just data—it's the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet's proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as 'may,' 'should,' 'expects,' 'anticipates,' 'contemplates,' 'estimates,' 'believes,' 'plans,' 'projected,' 'predicts,' 'potential,' or 'hopes' or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Bitcoin, including Bitcoin's volatility; and our ability to implement our Bitcoin treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
ETFs to Play on AI's Growing Momentum
Increasing investments in the AI and Tech market were a dominant theme on Wall Street last year, and the momentum shows no signs of slowing in 2025. This sustained momentum presents a compelling opportunity for investors, as ongoing initiatives and innovation continue to drive growth in the U.S. AI and technology market. Nvidia NVDA shares surged on Wednesday, briefly pushing its market cap above $4 trillion for the first time. This underscored growing investor and market enthusiasm surrounding the AI sector. Nvidia has now become the world's most valuable company, overtaking Microsoft MSFT and Apple AAPL, both of which previously hit the $3 trillion mark, hinting at the outsized influence of tech and tech-related firms on the broader market. This milestone not only highlights the accelerating momentum behind the AI and tech rally but also reflects the immense significance of the AI chipmaker and the technology sector to the broader stock market. According to Reuters, Nvidia's rally further highlights the rising dominance of the technology sector, which has become the largest component of the S&P 500. In fact, the tech sector's share of the index has grown to nearly one-third of total market value. Massive AI Investments to Propel U.S. Toward Tech Dominance With the global AI market projected to surpass $1 trillion by 2031, the field is emerging as an increasingly attractive investment opportunity. According to Statista, the U.S. AI market is expected to witness a CAGR of 26.95% from 2025 to 2031, reaching a valuation of $309.7 billion by 2031, cementing its position as the largest AI market globally. In addition to the optimistic growth forecasts, President Trump has repeatedly emphasized his ambition to make the United States the global leader in AI. This stance further reinforces the country's position as an ideal destination for AI-related investments. Experts remain bullish on the AI infrastructure trade, as global investors ramp up their commitments to the U.S. AI market. SoftBank's Masayoshi Son's proposal for the $1 trillion Arizona hub and President Trump's earlier announcement of the $500 billion 'Stargate' initiative highlights the growing momentum behind AI investments in the U.S. market. ETFs to Explore Below, we highlight funds that investors may consider to capitalize on the AI momentum. AI ETFs Increasing exposure to AI-focused funds presents a compelling opportunity for investors, driven by the growing momentum behind the AI and Tech market in the United States. These developments, along with robust market forecasts, make AI and tech-related ETFs a strategic addition to portfolios with long-term investment horizons. Investors can consider iShares U.S. Technology ETF IYW, Fidelity MSCI Information Technology Index ETF FTEC, Global X Artificial Intelligence & Technology ETF AIQ and iShares Global Tech ETF IXN and Global X Robotics & Artificial Intelligence ETF BOTZ. With a one-month average trading volume of about 795,000 shares, AIQ is the most liquid option, ideal for active trading strategies. IYW has also gathered an asset base of $22.08 billion, the largest among the other annual fees, FTEC is the cheapest option, charging 0.08%, more suitable for long-term investing. Uranium ETFs As demand for AI soars and clean energy needs grow, tech giants are turning to nuclear power to fuel energy-intensive data centers to train and operate the large-scale AI models used in generative AI applications. Data centers are energy-intensive, with AI applications consuming even more energy than traditional computing. As a result, most tech giants are shifting toward renewable energy to meet their growing energy needs and exploring nuclear energy as a power source. With an increasing focus on nuclear energy and uranium demand set to grow substantially, uranium ETFs are also an appealing strategic portfolio addition for the long term. Investors can consider Global X Uranium ETF URA, VanEck Uranium+Nuclear Energy ETF NLR, Sprott Junior Uranium Miners ETF URNJ and Themes Uranium & Nuclear ETF URAN to capitalize on the uranium market's upside potential. Want key ETF info delivered straight to your inbox? Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apple Inc. (AAPL): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Fidelity MSCI Information Technology Index ETF (FTEC): ETF Research Reports iShares U.S. Technology ETF (IYW): ETF Research Reports Global X Robotics & Artificial Intelligence ETF (BOTZ): ETF Research Reports iShares Global Tech ETF (IXN): ETF Research Reports VanEck Uranium and Nuclear ETF (NLR): ETF Research Reports Global X Uranium ETF (URA): ETF Research Reports Sprott Junior Uranium Miners ETF (URNJ): ETF Research Reports Themes Uranium & Nuclear ETF (URAN): ETF Research Reports
Globe and Mail
an hour ago
- Globe and Mail
Citigroup Declares Common Stock Dividend
The Board of Directors of Citigroup Inc. today declared a quarterly dividend on Citigroup's common stock of $0.60 per share, payable on August 22, 2025, to stockholders of record on August 4, 2025. The Board of Directors of Citigroup Inc. also declared dividends on Citigroup's preferred stock as follows: – 6.250% Fixed Rate/Floating Rate Noncumulative Preferred Stock, Series T, payable August 15, 2025, to holders of record on August 5, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $31.25 for each receipt held. – 4.000% Fixed Rate Reset Noncumulative Preferred Stock, Series W, payable September 10, 2025, to holders of record on August 29, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $10.00 for each receipt held. – 3.875% Fixed Rate Reset Noncumulative Preferred Stock, Series X, payable August 18, 2025, to holders of record on August 8, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $9.6875 for each receipt held. – 4.150% Fixed Rate Reset Noncumulative Preferred Stock, Series Y, payable August 15, 2025, to holders of record on August 5, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $10.375 for each receipt held. – 7.375% Fixed Rate Reset Noncumulative Preferred Stock, Series Z, payable August 15, 2025, to holders of record on August 5, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $18.4375 for each receipt held. – 7.625% Fixed Rate Reset Noncumulative Preferred Stock, Series AA, payable August 15, 2025, to holders of record on August 5, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $19.0625 for each receipt held. – 7.200% Fixed Rate Reset Noncumulative Preferred Stock, Series BB, payable August 15, 2025, to holders of record on August 5, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $18.00 for each receipt held. – 7.125% Fixed Rate Reset Noncumulative Preferred Stock, Series CC, payable August 15, 2025, to holders of record on August 5, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $17.8125 for each receipt held. – 7.000% Fixed Rate Reset Noncumulative Preferred Stock, Series DD, payable August 15, 2025, to holders of record on August 5, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $17.50 for each receipt held. – 6.750% Fixed Rate Reset Noncumulative Preferred Stock, Series EE, payable August 15, 2025, to holders of record on August 5, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $16.875 for each receipt held. – 6.950% Fixed Rate Reset Noncumulative Preferred Stock, Series FF, payable August 15, 2025, to holders of record on August 5, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $17.375 for each receipt held. About Citi Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in more than 180 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services.
Globe and Mail
an hour ago
- Globe and Mail
Epilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Epilepsy Pipeline Insight, 2025 ' report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epilepsy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Epilepsy pipeline products in this space. Explore our latest breakthroughs in Epilepsy Research. Learn more about our innovative pipeline today! @ Epilepsy Pipeline Outlook Key Takeaways from the Epilepsy Pipeline Report In June 2025, Ono Pharmaceutical Co. Ltd announced a Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures. In June 2025, UCB Biopharma SRL conducted a study is to evaluate the long-term safety and tolerability of brivaracetam. EP0156 is designed to assess the long-term safety and tolerability of BRV in pediatric study participants with epilepsy who participated in the neonatal study N01349 [NCG03325439] and/or have participated in the open-label, long-term, follow-up pediatric study N01266 [NCT01364597]. DelveInsight's Epilepsy pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Epilepsy treatment. The leading Epilepsy Companies such as UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others. Promising Epilepsy Pipeline Therapies such as Stiripentol, Lacosamide, Levetiracetam 250 mg, Cenobamate, Ganaxolone, Pregabalin, and others. Stay informed about the cutting-edge advancements in Epilepsy treatments. Download for updates and be a part of the revolution in Neurology Care @ Epilepsy Clinical Trials Assessment Epilepsy Emerging Drugs Profile EPX-100: Harmony Biosciences EPX-100 is a potential new treatment being for people with Dravet syndrome and Lennox-Gastaut Syndrome. EPX-100 is a repurposed antihistamine, which was used in the 1950s and 1960s to treat itchiness. The medication is thought to be able to suppress seizures through its action on the serotonin signaling pathways, a mechanism that is different from its anti-histaminic properties. Serotonin is a chemical messenger present in many parts of the brain. Scientists think that people with Dravet syndrome and Lennox-Gastaut Syndrome may have alterations in the serotonin signaling pathway, but the exact problems are not known. Likewise, precisely how EPX-100 affects serotonin systems in the brain to reduce seizures is still unclear. According to company's pipeline the drug is in the Phase III stage of its development for the treatment of Dravet syndrome and is in the Phase II stage of its development for the treatment of Lennox-Gastaut Syndrome. BMB-101: Bright Minds Biosciences BMB-101, a 5-HT2C selective and biased agonist, has demonstrated compelling activity in a host of in-vitro and in-vivo non-clinical tests. Compared to Locaserin, BMB-101 exhibits strong Gq signaling coupled with minimal beta-arrestin recruitment. Mechanistically, Serotonin (5- Hydroxytryptamine, 5-HT) is a monoamine neurotransmitter widely expressed in the central nervous system, and drugs modulating 5-HT have made a major impact in mental health disorders. Central 5-HT systems have long been associated with the control of ingestive behavior and the modulation of behavioral effects of psychostimulants, opioids, alcohol and nicotine. Results of clinical trials and animal studies indicate that 5-HT2C up receptor agonists may have therapeutic potential in the treatment of addiction by decreasing the intake of opioids as well as impulsive behavior that can escalate compulsive drug use. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Epilepsy. STK-001: Stoke Therapeutics STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Dravet Syndrome. NRTX-1001: Neurona Therapeutics NRTX-1001 inhibitory neurons are targeted to the seizure-onset zone to enhance GABAergic inhibition, reduce seizure activity, and repair the affected neural network. NRTX-1001 is delivered as a single, one-time dose and is intended to persist and provide long-term seizure suppression. In preclinical studies, NRTX-1001 has provided seizure-freedom to the majority of the cell treatment group and has not shown signs of dose-limiting toxicity. The preclinical safety and efficacy data have led to an FDA-cleared Phase I/II clinical trial of NRTX-1001 for drug-resistant temporal lobe epilepsy. IAMA-6: IAMA Therapeutics IAMA-6 is an orally administered small molecule therapeutics designed to directly target and inhibit NKCC1-associated neuronal hyperexcitability. The elevated activity of NKCC1 is implicated in various pathological conditions, underscoring the significant potential of NKCC1 inhibition in the treatment of both idiopathic and secondary forms of autism (autism spectrum disorder, or ASD), refractory epilepsy, Dravet Syndrome, and other neurological disorders. With the capability to be applied across multiple central nervous system (CNS) indications, IAMA-6 has demonstrated its safety and favorable tolerability in pre-clinical studies. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Epilepsy. The Epilepsy Pipeline Report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment. Epilepsy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market. Learn more about Epilepsy Drugs opportunities in our groundbreaking Epilepsy research and development projects @ Epilepsy Unmet Needs Epilepsy Companies UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others. Epilepsy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Epilepsy Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Epilepsy treatment by visiting our website. Stay informed about how we're transforming the future of Neurology @ Epilepsy Market Drivers and Barriers, and Future Perspectives Scope of the Epilepsy Pipeline Report Coverage- Global Epilepsy Companies- UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others. Epilepsy Pipeline Therapies- Stiripentol, Lacosamide, Levetiracetam 250 mg, Cenobamate, Ganaxolone, Pregabalin, and others. Epilepsy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Epilepsy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Epilepsy Pipeline on our website @ Epilepsy Emerging Drugs and Companies Table of Contents Introduction Executive Summary Epilepsy: Overview Pipeline Therapeutics Therapeutic Assessment Epilepsy– DelveInsight's Analytical Perspective Late Stage Products (Phase III) EPX-100: Harmony Biosciences Mid Stage Products (Phase II) BMB-101: Bright Minds Biosciences Early Stage Products (Phase I) IAMA-6: IAMA Therapeutics Preclinical and Discovery Stage Products NT102: Neuroene Therapeutics Inactive Products Epilepsy Key Companies Epilepsy Key Products Epilepsy- Unmet Needs Epilepsy- Market Drivers and Barriers Epilepsy- Future Perspectives and Conclusion Epilepsy Analyst Views Epilepsy Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
